JP2023515528A - ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法 - Google Patents

ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法 Download PDF

Info

Publication number
JP2023515528A
JP2023515528A JP2022550934A JP2022550934A JP2023515528A JP 2023515528 A JP2023515528 A JP 2023515528A JP 2022550934 A JP2022550934 A JP 2022550934A JP 2022550934 A JP2022550934 A JP 2022550934A JP 2023515528 A JP2023515528 A JP 2023515528A
Authority
JP
Japan
Prior art keywords
fenebrutinib
subject
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022550934A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021173740A5 (https=
JP2023515528A5 (https=
Inventor
ヒデキ ガレン，
エドモンド ホアトゥン トン，
オーレリアン ヴィアッコス，
ビューディンゲン， ハンス－クリスティアン フォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023515528A publication Critical patent/JP2023515528A/ja
Publication of JPWO2021173740A5 publication Critical patent/JPWO2021173740A5/ja
Publication of JP2023515528A5 publication Critical patent/JP2023515528A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
JP2022550934A 2020-02-28 2021-02-25 ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法 Withdrawn JP2023515528A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062982872P 2020-02-28 2020-02-28
US62/982,872 2020-02-28
US202063051756P 2020-07-14 2020-07-14
US63/051,756 2020-07-14
PCT/US2021/019502 WO2021173740A1 (en) 2020-02-28 2021-02-25 Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2023515528A true JP2023515528A (ja) 2023-04-13
JPWO2021173740A5 JPWO2021173740A5 (https=) 2024-03-04
JP2023515528A5 JP2023515528A5 (https=) 2024-03-04

Family

ID=74885089

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550934A Withdrawn JP2023515528A (ja) 2020-02-28 2021-02-25 ブルトン型チロシンキナーゼの阻害剤を使用する一次性進行型多発性硬化症の治療方法

Country Status (13)

Country Link
US (1) US20230091561A1 (https=)
EP (1) EP4110339A1 (https=)
JP (1) JP2023515528A (https=)
KR (1) KR20220148826A (https=)
CN (1) CN115175682A (https=)
AU (1) AU2021227674A1 (https=)
BR (1) BR112022017102A2 (https=)
CA (1) CA3170685A1 (https=)
CL (1) CL2022002317A1 (https=)
IL (1) IL295476A (https=)
MX (1) MX2022010513A (https=)
TW (1) TWI899163B (https=)
WO (1) WO2021173740A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021249129A1 (en) 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178973A1 (en) * 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
JP2018529747A (ja) * 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
WO2020016850A1 (en) * 2018-07-20 2020-01-23 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
EP4049660B1 (en) 2016-02-29 2025-02-19 F. Hoffmann-La Roche AG Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
AU2021249129A1 (en) * 2020-04-03 2022-10-20 F. Hoffmann-La Roche Ag Methods of treating relapsing Multiple Sclerosis using an inhibitor of Bruton's tyrosine kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018529747A (ja) * 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
WO2018178973A1 (en) * 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
WO2020016850A1 (en) * 2018-07-20 2020-01-23 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AARON GREGSON; ET AL: "EMERGING SMALL-MOLECULE TREATMENTS FOR MULTIPLE SCLEROSIS: FOCUS ON B CELLS 以下備考", F1000RESEARCH, vol. 8, JPN5023006365, March 2019 (2019-03-01), pages 245 - 1, ISSN: 0005530021 *
ANONYMOUS: "HISTORY OF CHANGES FOR STUDY: NCT04544449 (A STUDY TO EVALUATE THE EFFICACY AND SAFETY 以下備考２", CLINICALTRIALS.GOV, JPN5023006369, 10 September 2020 (2020-09-10), pages 1 - 14, ISSN: 0005530025 *
JAMES J CRAWFORD; ET AL: "DISCOVERY OF GDC-0853: A POTENT, SELECTIVE, AND NONCOVALENT BRUTON’S TYROSINE KINASE 以下備考", JOURNAL OF MEDICINAL CHEMISTRY, vol. VOL:61, NR:6, JPN5023006368, 19 February 2018 (2018-02-19), US, pages 2227 - 2245, ISSN: 0005530024 *
MARISA WEXLER: "MS PATIENTS SHOW FEWER NEW LESIONS IN PHASE 2 TRIAL OF SAR442168 BTK INHIBITOR, STUDY SHOWS", 【ONLINE】, JPN5023006367, 7 February 2020 (2020-02-07), pages 1 - 2, ISSN: 0005530023 *
MARISA WEXLER: "PHASE 3 TRIALS OF ORAL EVOBRUTINIB IN RELAPSING MS PATIENTS OPENING SOON, MD SERONO SAYS", 【ONLINE】, JPN5023006366, 23 September 2019 (2019-09-23), pages 1 - 2, ISSN: 0005530022 *

Also Published As

Publication number Publication date
CN115175682A (zh) 2022-10-11
KR20220148826A (ko) 2022-11-07
US20230091561A1 (en) 2023-03-23
WO2021173740A1 (en) 2021-09-02
CL2022002317A1 (es) 2023-03-03
EP4110339A1 (en) 2023-01-04
MX2022010513A (es) 2022-09-21
AU2021227674A1 (en) 2022-07-21
CA3170685A1 (en) 2021-09-02
TW202146022A (zh) 2021-12-16
TWI899163B (zh) 2025-10-01
IL295476A (en) 2022-10-01
BR112022017102A2 (pt) 2022-11-16

Similar Documents

Publication Publication Date Title
US12605376B2 (en) Methods of treating relapsing multiple sclerosis using an inhibitor of Bruton's tyrosine kinase
JP5905534B2 (ja) 多発性硬化症を治療する方法
TWI794885B (zh) 全身紅斑性狼瘡之治療
Ruocco et al. Life-threatening bullous dermatoses: Pemphigus vulgaris
US20240287176A1 (en) Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2023542878A (ja) 多発性硬化症を治療するためのｌｏｕ０６４
TWI899163B (zh) 使用布魯頓氏酪胺酸激酶之抑制劑來治療首發漸進型多發性硬化症之方法
EP3376869B1 (en) Treatment of autoimmune disease
RU2858696C2 (ru) Способы лечения первично-прогрессирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
RU2858695C2 (ru) Способы лечения рецидивирующего рассеянного склероза с применением ингибитора тирозинкиназы брутона
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase
CN112203660A (zh) 用于治疗银屑病关节炎的方法
CA3230303A1 (en) Cd40l-specific tn3-derived scaffolds for use in the treatment and prevention of rheumatoid arthritis
HK40087403A (zh) 使用布鲁顿氏酪氨酸激酶抑制剂治疗复发型多发性硬化症的方法
RU2824354C2 (ru) Способы лечения синдрома шегрена с применением ингибитора тирозинкиназы брутона
US20230340136A1 (en) Treatment of cll
WO2026024885A1 (en) Rilzabrutinib for treating warm antibody autoimmune hemolytic anemia
TW202210068A (zh) 用於治療家族性地中海型發熱病的cxcr-2抑制劑
HK40113661A (zh) Cd40l特异性tn3衍生支架及其用於治疗和预防类风湿性关节炎的方法
TW202539688A (zh) 使用索樂匹尼布處置溫型自體免疫性溶血性貧血的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260107

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260108